27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Pfizer Inc (NYSE:PFE) has provided an update on the Phase 2b study of vupanorsen, investigational antisense therapy for cardiovascular (CV) risk reduction and severe hypertriglyceridemia.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
- In the dose-ranging study in subjects with elevated non-HDL-C and triglycerides (TG), the study met its primary endpoint, achieving a statistically significant reduction in non-HDL-C at all doses tested at 24 weeks, compared to placebo.
- In addition, subjects treated with vupanorsen achieved statistically significant reductions in TG and ANGPTL3 at all dose levels at 24 weeks, compared to placebo.
- The topline results also showed that vupanorsen dose-dependently lowered its target, angiopoietin-like 3.
- Pfizer is continuing to review the findings to determine the next steps regarding future development.
- The most common adverse events were injection site reactions, which often occurred in the highest vupanorsen dose group.
- In November 2019, Pfizer licensed vupanorsen from Ionis Pharmaceuticals Inc (NASDAQ:IONS) in a worldwide exclusive agreement.
- Price Action: PFE shares are down 0.45% at $50.85, while IONS stock is down 4.39% at $29 during the market session on the last check Wednesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.